ICH Project Workshop on Points to Consider in the ICH Guidelines for Quality Implementation Working Group

November 09, 2012 The

International Council for Harmonisation of Technical Requirements for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has developed the Guidelines for "Drug Development" (Q8(R2)), "Quality Risk Management" (Q9) and "Quality System for Pharmaceuticals" (Q10) to promote progress in science and risk-based approaches to quality in pharmaceutical products. These guidelines have already entered into force in Japan. In order to clarify the common interpretation of these guidelines, the ICH Guidelines for Quality Implementation Working Group (Q-IWG) has developed six Points to Consider: "Guidelines for the implementation of ICH Q8, Q9 and Q10 approved by the ICH", which include The MHLW issued an administrative communication on June 15, 2012 for three items: "Criticality of Quality Characteristics and Process Parameters," "Management Strategy," and "Degree of Documentation in Marketing Authorization Applications with More Advanced Methods (QbD). The remaining three items ("Role of models in Quality by Design (QbD)", "Design space" and "Process validation/continuous process check") were issued on February 1, 2013.
Since these Points to Consider are important not only for clarifying the interpretation of ICH Q8, Q9, and Q10 Guidelines, but also for the application for approval and the revision of the GMP Enforcement Notification that is under consideration, we will take this opportunity to promote understanding and wide application of the Guidelines by holding Explanation Lectures on the "Points to Consider", Case Study Introductions, and Panel Discussions. The workshop will consist of lectures on the "Points to Consider," introduction of case studies, and panel discussion to promote understanding and wide application of the "Guidelines. The workshop was attended by approximately 300 participants from a wide range of companies, and a lively question-and-answer session was held during the panel discussion.
The program, lecture timetable, and presentation materials for this symposium are attached below as files for direct viewing.
Unauthorized copying or reproduction of the attached materials is strictly prohibited.

Date, time and place of the symposium

Date and Time Date and time
February 15, 2013 (Friday) 10:00-17:00 All Dentsu Labor Hall (All Dentsu Hall)
3-6 Kanda Surugadai, Chiyoda-ku, Tokyo
Tel. 03-3219-2211

Information and Program

Information and Program (313KB)

Lecture Materials

Presentations Speakers

00_Opening Remarks

Hironobu Saito (Daiichi Sankyo)

01_Introduction (409KB)

Eiji Ishikawa (Dainippon Sumitomo)

02. Criticality of quality characteristics and process parameters (825KB)

Yukio Hiyama (National Institute of Public Health)

03. Control strategy (591KB)

Tetsuhito TAKADA (Mochida Corporation)

04_Degree of documentation in marketing authorization applications using more advanced methods (QbD) (674KB)

Yoshihiro MATSUDA (NIHON Corporation)

05_Role of models in Quality by Design (QbD) (488KB)

Eiji Ishikawa (Dainippon Sumitomo)

06_Design space (658KB)

Kazuhiro OKOCHI (Takeda)

07_Process Validation/Continuous Process Verification (654KB)

Masatoshi MORISUE (NIHON GENERAL INDUSTRIAL CO., LTD.)

08_Background and Issues of Revision of GMP Enforcement Notification (1409KB)

Masatoshi MORISUE (NIMS)

09_Consideration from Sakura Mill case study (1600KB)

Kazunori Takagi (NIMS)

 

Share this page

TOP